


Under the auspices of



Melanoma  
World Society  
**MWS**



**Congress Presidents**  
Axel Hauschild, Kiel, Germany  
Christoffer Gebhardt, Hamburg, Germany

**2026 in Hamburg**

# 16<sup>th</sup> European Post-Chicago Melanoma / Skin Cancer Meeting

**Hamburg | Germany**  
**Radisson Blu Hotel**

[european-post-chicago-meeting.org](http://european-post-chicago-meeting.org)

**June**  
**25<sup>th</sup> – 26<sup>th</sup>**  
**2026**

**Preliminary  
Program**

updated: 12/06/2026

# CONTENT

---

>> WELCOME MESSAGE 03

---

>> PROGRAM AT A GLANCE 04

---

>> PROGRAM 06

Thursday, June 25<sup>th</sup>, 2026 06

Friday, June 26<sup>th</sup>, 2026 10

---

>> CONGRESS FACULTY 14

---

>> SATELLITE SYMPOSIA OVERVIEW 18

---

>> FLOOR PLAN 20

---

>> GENERAL INFORMATION 22

---

>> SPONSORS 24

---

# WELCOME MESSAGE

Dear colleagues and friends,

We are delighted to welcome you once again to the Interdisciplinary Global Conference on News in Melanoma / Skin Cancer – the “European Post-Chicago Meeting (EPCM)”!

Last year marked our very first time hosting the conference in the vibrant city of Hamburg, and the feedback was overwhelmingly positive. This enthusiastic response has encouraged us to return to Hamburg in 2026 – a setting that truly fosters inspiring exchange and scientific collaboration.

As always, you can look forward to stimulating topics that go far beyond the obvious, offering a deeper look into emerging developments in melanoma diagnostics and therapy. Additionally, we are excited to introduce new faces from the community of young oncologists, who will enrich our discussions with their innovative ideas and scientific curiosity.

With international key opinion leaders presenting cutting-edge research, sharing the latest clinical trial results, and participating in dynamic, forward-looking discussions, this year’s program continues our tradition of excellence.

**Welcome back to Hamburg – a place where valuable scientific insights meet a warm and familiar atmosphere.**

Best wishes,



Axel Hauschild, MD  
Congress President



Christoffer Gebhardt, MD  
Congress President



*"Dear colleagues and friends,*

*Another important transition this year is the change in leadership. After the honorable farewell of Professor Claus Garbe, who shaped this meeting for many years with remarkable dedication, I would like to express my sincere appreciation for his outstanding contributions to the EPCM and to the melanoma community at large.*

*At the same time, I am pleased to welcome Professor Christoffer Gebhardt as our new Co President. He has already proven to be an invaluable asset, bringing fresh perspectives and great commitment to the conference."*



Axel Hauschild, MD  
Congress President



# PROGRAM AT A GLANCE

## THURSDAY, JUNE 25<sup>th</sup>, 2026

	NEW YORK	SHANGHAI
8:00	Opening of the conference	
	<b>SYMPOSIUM I</b> My personal highlights at ASCO 2026	
9:00		
	<b>KEYNOTE LECTURE I</b>	
10:00	<b>SATELLITE SYMPOSIUM I</b>	
	BREAK	
11:00	<b>SATELLITE SYMPOSIUM II</b>	
12:00	<b>SYMPOSIUM II</b> Lifestyle factors impacting cancer treatment outcomes	<b>PARALLEL SYMPOSIUM I</b> Tumor board discussion: My most interesting non-melanoma cases
13:00		
	BREAK	
14:00	<b>SATELLITE SYMPOSIUM III</b>	
15:00	<b>SYMPOSIUM III</b> Merkel Cell Carcinoma	<b>PARALLEL SYMPOSIUM II</b> Registry data and studies: Update 2026
16:00	BREAK	
	<b>SYMPOSIUM IV</b> Treatment of vulnerable skin cancer patients	
17:00		<b>PARALLEL SYMPOSIUM III</b> Rare skin cancers
	<b>SYMPOSIUM V</b> Adverse event management for ICI	
18:00		
19:00		

# FRIDAY, JUNE 26<sup>th</sup>, 2026

	NEW YORK	SHANGHAI
8:00	<b>SYMPOSIUM VI</b> GEP – Gene expression profiling	<b>PARALLEL SYMPOSIUM IV</b> Tumor board discussion: My most interesting melanoma cases
9:00	<b>SYMPOSIUM VII</b> EADO guidelines 2026 for various skin cancers: What’s new?	<b>PARALLEL SYMPOSIUM V</b> Melanoma brain mets: still difficult to treat
10:00	<b>SYMPOSIUM VIII</b> ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas	
11:00	<b>SATELLITE SYMPOSIUM IV</b>	
	BREAK	
12:00	<b>KEYNOTE LECTURE II</b>	
	<b>KEYNOTE LECTURE III</b>	
13:00	BREAK	
14:00	<b>SATELLITE SYMPOSIUM V</b>	
	<b>SYMPOSIUM IX</b> Is the abscopal effect of radiotherapy existing?	
15:00	<b>SYMPOSIUM X</b> Adjuvant treatment of melanoma	
16:00	<b>CLOSING REMARKS</b>	
17:00		
18:00		
19:00		

# THURSDAY, JUNE 25<sup>th</sup>, 2026

08:00

NEW YORK

## OPENING OF THE CONFERENCE

CHRISTOFFER GEBHARDT, HAMBURG, GERMANY

08:10–09:30

NEW YORK

## SYMPOSIUM I

My personal highlights at ASCO 2026

CHAIRPERSONS: CLAUS GARBE, TUEBINGEN, GERMANY  
JOSEP MALVEHY, BARCELONA, SPAIN

08:10–08:40 ... in melanoma

**Georgina Long, Sydney, Australia**

08:50–09:20 ... in non-melanoma skin cancer

**Dirk Schadendorf, Essen, Germany**

09:30–10:00

NEW YORK

## KEYNOTE LECTURE I

CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY

Dermoscopy for the detection of all skin cancers?!

**Aimilios Lallas, Thessaloniki, Greece**

10:00–10:45

NEW YORK

## SATELLITE SYMPOSIUM I

Gold Sponsor

SEE PROGRAM ON PAGE 18

10:45–11:00

## BREAK

11:00–12:00

NEW YORK

## SATELLITE SYMPOSIUM II

Platinum Sponsor

SEE PROGRAM ON PAGE 18

12:00–13:00

NEW YORK

## SYMPOSIUM II

Lifestyle factors impacting cancer treatment outcomes

CHAIRPERSONS: FRANK MEISS, FREIBURG, GERMANY  
LISA ZIMMER, ESSEN, GERMANY

12:00–12:15 Exercise

**Joachim Wiskemann, Heidelberg, Germany**

12:20–12:35 Nutrition

**Reinhard Dummer, Zurich, Switzerland**

12:40–12:55 Timing of ICI administration

**Sapna Patel, Denver, USA**

# THURSDAY, JUNE 25<sup>th</sup>, 2026

12:00–13:00

SHANGHAI

## PARALLEL SYMPOSIUM I

Tumor board discussion:

My most interesting non-melanoma cases

DISCUSSANTS: PETR ARENBERGER, PRAGUE, CZECH REPUBLIC  
ZELJKO MIJUSKOVIC, BELGRADE, SERBIA  
BERENICE LANG, FRANKFURT, GERMANY

13:00–14:00

BREAK

14:00–15:00

NEW YORK

## SATELLITE SYMPOSIUM III

Platinum Sponsor

SEE PROGRAM ON PAGE 18

15:00–16:00

NEW YORK

## SYMPOSIUM III

Merkel Cell Carcinoma

CHAIRPERSONS: MARIO MANDALÀ, PERUGIA, ITALY  
DIRK SCHADENDORF, ESSEN, GERMANY

15:00–15:15 Adjuvant and neoadjuvant trials

**Dirk Schadendorf, Essen, Germany**

15:15–15:30 Role of irradiation for MCC

**Joanna Mangana, Zurich, Switzerland**

15:30–15:45 Treatment for advanced MCC

**Celeste Lebbé, Paris, France**

15:45–16:00 Discussion

# THURSDAY, JUNE 25<sup>th</sup>, 2026

15:00–17:00

SHANGHAI

## PARALLEL SYMPOSIUM II

Registry data and studies: Update 2026

CHAIRPERSONS: LIDIJA KANDOLF, BELGRADE, SERBIA  
JOSEP MALVEHY, BARCELONA, SPAIN  
MICHAEL WEICHENTHAL, KIEL, GERMANY

- 15:00–15:10 Studies from the EuMelareg  
**Michael Weichenthal, Kiel, Germany**
- 15:15–15:25 Studies from the ADOREG  
**Selma Ugurel, Bielefeld, Germany**
- 15:30–15:40 Studies from the Xarxa Melanoma database in Catalonia  
**Josep Malvehy, Barcelona, Spain**
- 15:45–15:55 Studies from the SERIO registry  
**Lucie Heinzerling, Munich, Germany**
- 16:00–16:10 Access to medicines for melanoma in Europe  
**Lidija Kandolf, Belgrade, Serbia**
- 16:15–16:25 Studies from the EORTC  
**Mario Mandalà, Perugia, Italy**
- 16:30–16:40 Studies from the Caraderm  
**Celeste Lebbé, Paris, France**
- 16:45–17:00 Discussion

16:00–16:15

BREAK

16:15–17:15

NEW YORK

## SYMPOSIUM IV

Treatment of vulnerable skin cancer patients

CHAIRPERSONS: THOMAS EIGENTLER, BERLIN, GERMANY  
HEATHER SHAW, LONDON, UNITED KINGDOM

- 16:15–16:30 Family planning  
**Heather Shaw, London, United Kingdom**
- 16:35–16:50 Old and frail patients  
**Rodrigo Munhoz, Sao Paulo, Brazil**
- 16:55–17:10 Immunocompromised patients  
**Ulrike Leiter-Stoeppeke, Tuebingen, Germany**

# THURSDAY, JUNE 25<sup>th</sup>, 2026

17:00–18:00

SHANGHAI

## PARALLEL SYMPOSIUM III

Rare skin cancers

CHAIRPERSONS: CHRISTINA MITTELDORF, GOETTINGEN, GERMANY  
MIRIAM MENGONI, LUEBECK, GERMANY

17:00–17:15 Rare Cutaneous Lymphomas  
**Christina Mitteldorf, Goettingen, Germany**

17:20–17:35 Cutaneous angiosarcomas  
**Philippe Saiag, Paris, France**

17:40–17:55 Adnexal skin cancers  
**Selma Ugurel, Bielefeld, Germany**

17:15–18:15

NEW YORK

## SYMPOSIUM V

Adverse event management for ICI

CHAIRPERSONS: KATHARINA KAEHLER, KIEL, GERMANY  
MIRJANA ZIEMER, LEIPZIG, GERMANY

17:15–17:30 Long-term toxicities / delayed onset toxicities  
**Rodrigo Munhoz, Sao Paulo, Brazil**

17:35–17:50 ICI rechallenge after immune-related adverse events  
**Christoph Hoeller, Vienna, Austria**

17:55–18:10 What you should know about differences of  
various immunosuppressants  
**Katharina Kaehler, Kiel, Germany**

# FRIDAY, JUNE 26<sup>th</sup>, 2026

08:00–09:00

NEW YORK

## SYMPOSIUM VI

### GEP – Gene expression profiling

CHAIRPERSONS: JULIAN KOETT, HAMBURG, GERMANY  
TERESA AMARAL, STRASBOURG, FRANCE

08:00–08:15 Which test is the best for melanoma?

**Teresa Amaral, Strasbourg, France**

08:15–08:30 What can we learn from Breast Cancer (Oncotype DX Test)?

**Marc Thill, Frankfurt, Germany**

08:30–08:45 How to implement GEP in melanoma guidelines?

**Merrick I. Ross, Houston, USA**

08:45–09:00 Discussion

08:00–09:00

SHANGHAI

## PARALLEL SYMPOSIUM IV

### Tumor board discussion: My most interesting melanoma cases

DISCUSSANTS: UGUR USLU, WUERZBURG, GERMANY  
PETER KOELBLINGER, SALZBURG, AUSTRIA  
JENNIFER LANDSBERG, BONN, GERMANY

09:00–10:00

NEW YORK

## SYMPOSIUM VII

### EADO guidelines 2026 for various skin cancers: What's new?

CHAIRPERSONS: LIEVE BROCHEZ, GENT, BELGIUM  
GLENN GEIDEL, HAMBURG, GERMANY

09:00–09:18 ... basal cell carcinoma (BCC)

**Nicole Kelleners-Smeets, Maastricht, The Netherlands**

09:18–09:36 ... cutaneous squamous cell carcinoma (CSCC)

**Alexander Stratigos, Athens, Greece**

09:36–09:54 ...current trials for BCC/CSCC with future implications

**Ralf Gutzmer, Minden, Germany**

09:00–10:00

SHANGHAI

## PARALLEL SYMPOSIUM V

### Melanoma brain mets: still difficult to treat

CHAIRPERSON: FRIEDEGUND MEIER, DRESDEN, GERMANY

09:00–09:15 AI detection of brain mets replacing radiologists?

**Alexander Radbruch, Bonn, Germany**

09:15–09:30 Can we prevent brain mets?

**James Larkin, London, United Kingdom**

09:30–09:45 Standard of care in systemic treatment

**Janice M. Mehnert, New York, USA**

09:45–10:00 Experimental approaches to treat brain mets

**Friedegund Meier, Dresden, Germany**

# FRIDAY, JUNE 26<sup>th</sup>, 2026

10:00–10:45

NEW YORK

## SYMPOSIUM VIII

ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas

CHAIRPERSONS: CAROLA BERKING, ERLANGEN, GERMANY  
SEBASTIAN HAFERKAMP, HALLE, GERMANY

10:00–10:15 Treatment of metastatic ocular melanoma:  
it's a whole new world!

**Paul Nathan, Northwood, United Kingdom**

10:15–10:35 Tebentafusp, Brenetafusp and other ImmTACs not only for  
uveal melanoma

**Jessica Hassel, Heidelberg, Germany**

10:35–10:45 Discussion

10:45–11:30

NEW YORK

## SATELLITE SYMPOSIUM IV

Gold Sponsor

SEE PROGRAM ON PAGE 19

11:30–11:45

BREAK

11:45–12:15

NEW YORK

## KEYNOTE LECTURE II

CHAIRPERSON: CAROLA BERKING, ERLANGEN, GERMANY

Personalized oncology: already reality or just a dream?

**Olivier Michielin, Geneva, Switzerland**

12:15–12:45

NEW YORK

## KEYNOTE LECTURE III

CHAIRPERSON: CHRISTOFFER GEBHARDT, HAMBURG, GERMANY

Neoadjuvant or perioperative treatment for melanoma?

**Sapna Patel, Denver, USA**

12:45–13:45

BREAK

13:45–14:15

NEW YORK

## SATELLITE SYMPOSIUM V

SEE PROGRAM ON PAGE 19

# FRIDAY, JUNE 26<sup>th</sup>, 2026

14:15–15:00

NEW YORK

## SYMPOSIUM IX

Is the abscopal effect of radiotherapy existing?

CHAIRPERSONS: ELISABETH LIVINGSTONE, ESSEN, GERMANY  
MERRICK I. ROSS, HOUSTON, USA

14:15–14:30 Yes

**Luca Tagliaferri, Rome, Italy**

14:30–14:45 No

**Alexander Eggermont, Utrecht, The Netherlands**

14:45–15:00 Panel Discussion

15:00–16:00

NEW YORK

## SYMPOSIUM X

Adjuvant treatment of melanoma

CHAIRPERSONS: ANDREA FORSCHNER, TUEBINGEN, GERMANY  
PETER MOHR, BUXTEHUDE, GERMANY

15:00–15:20 Targeted therapy or immune checkpoint inhibition for BRAF mutated stage III patients?

**Mario Mandalà, Perugia, Italy**

15:20–15:40 Is combo immune checkpoint inhibition replacing single agent anti-PD1?

**Janice M. Mehnert, New York, USA**

15:40–16:00 How long is long enough?

**Bastian Schilling, Frankfurt, Germany**

16:00

NEW YORK

## CLOSING REMARKS

AXEL HAUSCHILD, KIEL, GERMANY

# Congress On-Demand

**All approved lectures from the main meeting room will be available on the On-Demand platform from June 30, 2026 until September 30, 2026.**

The on-demand service is available to all registered attendees (F2F and virtual).

**THE AREA  
IS PASSWORD  
PROTECTED**

Access to the On-Demand area is granted using the same login credentials as for the virtual platform.

# CONGRESS FACULTY

## A

---

**Teresa Amaral, MD**

Institut Public de Cancerologie  
Strauss Europe  
Strasbourg, France

**Petr Arenberger, MD**

Charles University Prague  
Prague, Czech Republic

## B

---

**Carola Berking, MD**

Director of the Department of Dermatology  
University Hospital Erlangen  
Erlangen, Germany

**Lieve Brochez, MD**

Gent University Hospital (UZ Gent)  
Department of Dermatology –  
Gent University Hospital  
Gent, Belgium

## D

---

**Reinhard Dummer, MD**

Deputy Clinical Director  
Department of Dermatology  
University of Zurich  
Zurich, Switzerland

## E

---

**Alexander Eggemont, MD**

Princess Máxima Center for  
Pediatric Oncology  
CS Utrecht, Netherlands

**Thomas Eigentler, MD**

Skin Tumor Center  
Charité University Clinic Berlin  
Berlin, Germany

## F

---

**Andrea Forschner, MD**

University Hospital Tuebingen  
Tuebingen, Germany

## G

---

**Claus Garbe, MD**

Eberhard Karls University  
University Hospital Tuebingen  
Tuebingen, Germany

**Christoffer Gebhardt, MD**

University Medical Center  
Hamburg-Eppendorf  
Hamburg, Germany

**Glenn Geidel, MD**

University Medical Center  
Hamburg-Eppendorf  
Hamburg, Germany

**Ralf Gutzmer, MD**

Johannes Wesling Klinikum Minden  
Minden, Germany

## H

---

**Sebastian Haferkamp, MD**

University Hospital Regensburg  
Department and Outpatient Clinic  
of Dermatology  
Regensburg, Germany

**Jessica Hassel, MD**

National Center for Tumor Diseases (NCT)  
Heidelberg, Germany

**Axel Hauschild, MD**

University Hospital Schleswig-Holstein,  
Kiel Campus, Department of Dermatology  
and Venereology  
Kiel, Germany

**Lucie Heinzerling, MD**

LMU University Hospital  
Skin Cancer Center at CCC Munich  
Munich, Germany

**Christoph Hoeller, MD**

Department of Dermatology  
Medical University of Vienna  
Vienna, Austria

## K

---

**Katharina Kaehler, MD**

University Hospital Schleswig-Holstein,  
Kiel Campus, Department of Dermatology  
and Venereology  
Kiel, Germany

**Lidija Kandolf, MD**

Clinical Center of Serbia  
Belgrade, Serbia

**Nicole Kelleners-Smeets, MD**

Maastricht University Medical Center+  
(MUMC+)  
Maastricht, The Netherlands

**Peter Koelblinger, MD**

Dermatology Office  
Salzburg, Austria

**Julian Koett, MD**

Clinic of Dermatology and Venereology  
University Hospital Hamburg  
Hamburg, Germany

## L

---

**Aimilios Lallas, MD**

Aristotle University of Thessaloniki  
Hospital of Skin and Venereal  
Diseases  
Thessaloniki, Greece

**Jennifer Landsberg, MD**

Center for Skin Diseases  
Department of Dermato-Oncology &  
Phlebology  
University Hospital Bonn (AÖR),  
Bonn, Germany

**Berenice Lang, MD**

Skin Cancer Center/Department of  
Dermatology, Venereology and Allergology  
University Hospital Frankfurt  
Frankfurt am Main, Germany

**James Larkin, MD**

The Royal Marsden/Institute of  
Cancer Research  
London, United Kingdom

**Celeste Lebbé, MD**

Hôpital Saint-Louis  
Paris, France

**Ulrike Leiter-Stoepcke, MD**

University Hospital Tuebingen  
Tuebingen, Germany

**Elisabeth Livingstone, MD**

University Hospital Essen  
Essen, Germany

**Georgina Long, MD**

Melanoma Institute Australia  
Sydney, Australia

## M

---

**Josep Malvehy, MD**

Hospital Clínic de Barcelona  
Barcelona, Spain

**Mario Mandalà, MD**

University of Perugia  
Perugia, Italy

**Joanna Mangana, MD**

University Hospital Zurich –  
Dermatology Clinic  
Zurich, Switzerland

**Janice M. Mehnert, M.D.**

NYU Grossman School of Medicine  
Laura and Isaac Perlmutter Cancer  
Center at NYU  
New York, USA

**Friedegund Meier, MD**

University Hospital Carl Gustav  
Carus Dresden  
Dresden, Germany

**Frank Meiss, MD**

Skin Tumor Center of the Tumor  
Center Freiburg – CCCF  
University Hospital Freiburg  
Freiburg, Germany

**Miriam Mengoni, MD**

University Medical Center  
Schleswig-Holstein (UKSH)  
Campus Luebeck  
Luebeck, Germany

**Olivier Michielin, MD**

Geneva University Hospitals  
Geneva, Switzerland

**Zeljko Mijuskovic, MD**

Military Medical Academy  
Belgrade, Serbia

**Christina Mitteldorf, MD**

University Medical Center Goettingen (UMG)  
Department of Dermatology,  
Venereology and Allergology  
Goettingen, Germany

**Peter Mohr, MD**

Elbe Klinikum Buxtehude  
Buxtehude, Germany

**Rodrigo Munhoz, MD**

Cancer Institute of the State of São Paulo  
São Paulo, Brazil

## N

---

**Paul Nathan, MD**

Mount Vernon Cancer Centre  
Northwood, United Kingdom

## P

---

**Sapna Patel, MD**

University of Colorado Cancer Center  
Denver, USA

## R

---

**Alexander Radbruch, MD**

University Hospital Bonn  
Bonn, Germany

**Merrick I. Ross, MD**

University of Texas  
Department of Surgical Oncology,  
Division of Surgery  
Houston, USA

**S**

---

**Philippe Saiag, MD**

Dermatology Department  
Hôpital Ambroise-Paré  
Boulogne-Billancourt, France

**Dirk Schadendorf, MD**

Comprehensive Cancer Center  
University Hospital Essen & Research  
Alliance Ruhr, Research Center One Health,  
University Duisburg-Essen  
Essen, Germany

**Bastian Schilling, MD**

University Hospital Frankfurt  
Frankfurt, Germany

**Heather Shaw, MD**

University College London Hospitals  
NHS Foundation Trust  
London, United Kingdom

**Alexander Stratigos, MD**

National and Kapodistrian  
University of Athens  
Athens, Greece

**T**

---

**Luca Tagliaferri, MD**

Agostino Gemelli University Hospital  
Rome, Italy

**Marc Thill, MD**

Agaplesion Markus Hospital  
Clinic for Gynaecology and  
Gynaecological Oncology  
Frankfurt am Main, Germany

**U**

---

**Selma Ugurel, MD**

Department of Dermatology,  
Bielefeld University, Medical School and  
University Medical Center OWL  
Bielefeld, Germany

**Ugur Uslu, MD**

Department of Dermatology,  
Venereology and Allergology  
University Hospital Wuerzburg  
Wuerzburg, Germany

**W**

---

**Michael Weichenthal, MD**

University Hospital Schleswig-Holstein,  
Kiel Campus, Department of Dermatology  
and Venereology  
Kiel, Germany

**Joachim Wiskemann, MD**

National Center for Tumor Diseases  
(NCT) Heidelberg  
Heidelberg, Germany

**Z**

---

**Mirjana Ziemer, MD**

Skin Tumor Center  
University Hospital Leipzig  
Leipzig, Germany

**Lisa Zimmer, MD**

University Hospital Essen  
Essen, Germany

# SATELLITE SYMPOSIA OVERVIEW

THURSDAY, JUNE 25<sup>th</sup>, 2026

---

10:00–10:45 SATELLITE SYMPOSIUM I

## **DELCATH**

**Nuances in Metastatic Uveal Melanoma Care A Global Dialogue on current Clinical Practice, Treatment Algorithms and Emerging Insights**

CHAIR: REINHARD DUMMER, ZURICH, SWITZERLAND

Through open dialogue and contrasting perspectives, leading experts will explore how guidelines, clinical experience, and emerging data intersect – and where they fall short. The programme embraces diverse viewpoints and thoughtful discussion, highlighting the complex reality of clinical practice and real-world decision-making across varied healthcare settings.

**Christoffer Gebhardt, Hamburg, Germany**

**Christoph Hoeller, Vienna, Austria**

**Sapna Patel, Denver, USA**

---

11:00–12:00 SATELLITE SYMPOSIUM II

## **REGENERON** Platinum Sponsor

**Advancing Treatment Pathways in Cutaneous Squamous Cell Carcinoma: Patients to Practice**

11:00–11:03 Welcome and Introductions

**Axel Hauschild, Kiel, Germany**

11:03–11:18 Identification of Patients with CSCC at High-risk of Recurrence

**Heather Shaw, London, United Kingdom**

11:18–11:33 Integrating Systemic Therapy in Perioperative Care for CSCC

**Ralf Gutzmer, Minden, Germany**

11:33–11:45 Q&A/Discussion

**All Faculty**

---

14:00–15:00 SATELLITE SYMPOSIUM III

## **MSD** Platinum Sponsor

**Early-Stage Melanoma in Daily Practice:  
Are We Ready for Individualized Therapy?**

CHAIR: DIRK SCHADENDORF, ESSEN, GERMANY

14:00–14:05 Welcome and Introductions

**Dirk Schadendorf, Essen, Germany**

14:05–14:20 Residual risk after complete resection

**Christoffer Gebhardt, Hamburg, Germany**

14:20–14:35 Individualized therapy in resected high-risk melanoma

**Janice M. Mehnert, New York, USA**

14:35–14:50 Clinical Application of Individualized therapies

**Ahmad Ali Tarhini, Tampa, USA**

14:50–15:00 Q&A

**All Faculty**

## FRIDAY, JUNE 26<sup>th</sup>, 2026

---

10:45–11:30 SATELLITE SYMPOSIUM IV  
**BMS** Gold Sponsor  
**Redefining Melanoma Care 2026: Innovation, Evidence, Outcomes**  
CHAIR: AXEL HAUSCHILD, KIEL, GERMANY  
An Expert Panel with:  
**Christoph Hoeller, Vienna, Austria**  
**Christoffer Gebhardt, Hamburg, Germany**  
**Axel Hauschild, Kiel, Germany**

---

13:45–14:15 SATELLITE SYMPOSIUM V  
**MERCK**  
**Immune checkpoint inhibitors in Merkel cell carcinoma:  
10 years of progress from 2016 to 2026**

13:45–14:00 History and Current Role of Immune Checkpoint Inhibitors in MCC  
**Axel Hauschild, Kiel, Germany**


14:00–14:10 Latest Findings from Immune Checkpoint Inhibitor Trials in MCC  
**Maximilian Haist, Mainz, Germany**

14:10–14:15 Q&A  
**All Faculty**

# FLOOR PLAN

## RADISSON BLU HOTEL HAMBURG

### FIRST FLOOR



**Save the Date**

**June  
17<sup>th</sup>-18<sup>th</sup>  
2027**

**Hamburg | Germany  
Radisson Blu Hotel**

**Hamburg**

## **17<sup>th</sup> European Post-Chicago Melanoma/Skin Cancer Meeting**

**Congress Presidents**

Axel Hauschild, Kiel, Germany  
Christoffer Gebhardt, Hamburg, Germany

**SAVE  
THE  
DATE**

## **15<sup>th</sup> EUROPEAN SCHOOL OF DERMATO-ONCOLOGY**

**AN INTERACTIVE COURSE MEETING**

**JUNE 18<sup>TH</sup>-19<sup>TH</sup>, 2027**

**RADISSON BLU HOTEL  
HAMBURG, GERMANY**



**Course Directors**  
Axel Hauschild, Kiel, Germany  
Christoffer Gebhardt, Hamburg, Germany

# GENERAL INFORMATION

## CME Credits

The European Post-Chicago Melanoma/Skin Cancer Meeting 2026 has been submitted for accreditation to the UEMS-EACCME® (European Accreditation Council for Continuing Medical Education).

Once the accreditation process is completed, we will provide information regarding the number of CME credits awarded. Certificates of attendance will be issued after the meeting in accordance with EACCME® requirements.

## Congress Date

June 25<sup>th</sup>–June 26<sup>th</sup>, 2026

## Congress Organization



Gesellschaft für medizinische Projekte mbH  
Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany  
info@medconcept.org | www.medconcept.org  
Phone +49 (0)3342 42689-30 | Fax +49 (0)3342 42689-40

## Congress Venue

Radisson Blu Hotel Hamburg  
Congresspl. 2, 20355 Hamburg, Germany  
Phone: +49 (0)40 3502 3100 | E-Mail: info.hamburg@radissonblu.com

## Exhibition

A commercial exhibition will be held at the congress venue, close to the main rooms.

### Exhibition Opening Hours

Thursday, June 25 <sup>th</sup> , 2026	07:30–18:30
Friday, June 26 <sup>th</sup> , 2026	07:30–18:00

## Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements with respect to health and travel insurance.

## Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

## Registration and Information Desk

The registration desk is situated at the ground floor of the Radisson Blu Hotel to the right of the reception and in front of the meeting area entrance.

### Registration Desk Opening Hours

Thursday, June 25<sup>th</sup>, 2026 07:00–19:00  
Friday, June 26<sup>th</sup>, 2026 07:30–18:00

### Registration Fees

Virtual packages and on-demand service is included in all ticket categories.

	Presence Tickets			Virtual Tickets
	Early Bird until May 1 <sup>st</sup> , 2026	Regular Fee until June 16 <sup>th</sup> , 2026	Late	
Full Delegate Ticket	400 euros	500 euros	600 euros	400 euros
EADO Members	300 euros	400 euros	500 euros	300 euros
Students/Nurses Ticket*	150 euros	200 euros	250 euros	150 euros
Eastern European Countries*	150 euros	200 euros	250 euros	150 euros
Residents*	150 euros	200 euros	250 euros	150 euros

\*Please upload proof of university or clinic for students/nurse ticket, and proof of residence in a european eastern country for reduced tickets of this category, during registration process.

# SPONSORS

## PLATINUM



REGENERON

## GOLD



## BRONZE

Delcath

IMMUNOCORE

NOVARTIS



## EXHIBITORS AND SPONSORS

MERCK

16th European Post-Chicago Melanoma/Skin  
Cancer Meeting 2026 Satellite Symposium

# Advancing Treatment Pathways in Cutaneous Squamous Cell Carcinoma: Patients to Practice

**Thursday, 25 June**

11:00–12:00 CEST



**Prof. Axel Hauschild**  
(Chair)

*University Hospital  
Schleswig-Holstein  
(UKSH)  
Kiel, Germany*



**Dr. Heather M. Shaw**

*University College London  
Hospital and Mount Vernon  
Cancer Centre  
London, UK*



**Prof. Ralf Gutzmer**  
*Ruhr University and  
Johannes Wesling  
Medical Center  
Minden, Germany*


## 16th European Post-Chicago Melanoma/Skin Cancer Meeting

**25–26 June 2026**

Hamburg, Germany  
Radisson Blu Hotel Hamburg

This symposium is intended for healthcare professionals (HCPs) only; however, it is not intended for HCPs from the United Kingdom. It has been organised and fully sponsored by Regeneron Pharmaceuticals, Inc. DE-CEM-EM-26-03-0001 April 2026

**REGENERON®**



Everyday



Friends, Fun



Family



Autonomous



Hobbies, Recovery

**50%**  
fewer infusions  
with Q6W  
compared to Q3W\*



## New possibilities with KEYTRUDA®.

In adults either 200 mg every 3 weeks (Q3W)  
or 400 mg every 6 weeks (Q6W)\*

Further information on  
adjunct KEYTRUDA® treatment  
is available here



Prescribing  
information for  
KEYTRUDA®



\* The recommended dose of KEYTRUDA® in adults is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes. The recommended dose of KEYTRUDA® as monotherapy in paediatric patients aged 12 years and older with melanoma is 2 mg/kg body weight (bw) (up to a maximum of 200 mg), every 3 weeks (Q3W) administered as an intravenous infusion over 30 minutes.

MSD Sharp & Dohme GmbH | Levelingstr. 4a | 81673 München | www.msd.de  
MSD MedInfo | Telefon: +49 89 20 300 4500 | E-Mail: medinfo@msd.de

Please read the prescribing information  
for KEYTRUDA® before using it.



# FÜR EINE **ZUKUNFT** VOLLER MÖGLICHKEITEN.

**OPDUALAG®** setzt neue Maßstäbe in der Wirksamkeit gegenüber Nivolumab bei gleichzeitig guter Lebensqualität.<sup>1,2</sup>

Jetzt  
verfügbar

**Opdualag®**  
(nivolumab / relatlimab)

## Fortgeschrittenes Melanom\*

Im 4-Jahres-Update zeigte OPDUALAG® vs. Nivolumab bei Patient:innen mit PD-L1 < 1%:<sup>3,4</sup>

- Verdopplung des medianen progressionsfreien Überlebens
- 1/3 höhere Ansprechrate

\* OPDUALAG® ist für die Erstlinienbehandlung des fortgeschrittenen (nicht resezierbaren oder metastasierten) Melanoms mit Tumorzell-PD-L1-Expression < 1% bei Erwachsenen und Jugendlichen im Alter ab 12 Jahren indiziert!

1. OPDUALAG®-Fachinformation, aktueller Stand. 2. Schadendorf D et al. SMR Annual Meeting, 2021; Presentation. 3. Bristol Myers Squibb: Data on File. 4. Lipson EJ et al. Eur J Cancer, 2025; 225: 115547, Supplemental Appendix.

**OPDUALAG®** 240mg/80mg Konzentrat zur Herstellung einer Infusionslösung. **Wirkstoffe:** Nivolumab, Relatlimab. **Sonst. Bestandteile:** Histidin, Histidinhydrochlorid Monohydrat, Saccharose, Diethylentriamin-pentaessigsäure (Pentetsäure), Polysorbat 80 (E 433), Wasser für Injektionszwecke. **Anwendungsgebiet:** Erstlinienbehandlung des fortgeschrittenen (nicht resezierbaren oder metastasierten) Melanoms mit Tumorzell PD L1 Expression < 1% bei Erwachsenen und Jugendlichen im Alter ab 12 Jahren. **Gegenanzeigen:** Überempfindlichkeit gegen den Wirkstoff oder sonstige Bestandteile. **Nebenwirkungen: Sehr häufig:** Harnwegsinfektion; Anämie; Lymphopenie; Neutropenie; Leukopenie; Hypothyreose; Verminderter Appetit; Kopfschmerzen; Dyspnoe; Husten; Diarrhö; Erbrechen; Übelkeit; Abdominalschmerzen; Obstipation; Ausschlag; Vitiligo; Pruritus; Muskel- und Skelettschmerzen; Arthralgie; Ermüdung/Fatigue; Fieber; AST Anstieg; ALT Anstieg; Hyponatriämie; Kreatinin Anstieg; Anstieg der alkalischen Phosphatase; Hyperkaliämie; Hypokalziämie; Hypomagnesiämie; Hyperkalziämie; Hypokaliämie. **Häufig:** Infektion der oberen Atemwege; Thrombozytopenie; Eosinophilie; Nebenniereninsuffizienz; Hypophysitis; Hyperthyreose; Thyroiditis; Diabetes mellitus; Hypoglykämie; Gewichtsverlust; Hyperurikämie; Hypoalbuminämie; Dehydrierung; Verwirrheitszustand; Periphere Neuropathie; Schwindelgefühl; Dysgeusie; Uveitis; Sehverschlechterung; trockene Augen; vermehrte Tränensekretion; Myokarditis; Phlebitis; Pneumonitis; Nasenverstopfung; Kolitis; Pankreatitis; Gastritis; Dysphagie; Stomatitis; trockener Mund; Hepatitis; Alopezie; lichenoidale Keratose; Lichtempfindlichkeitsreaktion; trockene Haut; Arthritis; Muskelspasmen; muskuläre Schwäche; Nierenversagen; Proteinurie; Ödeme; grippeähnliche Erkrankungen; Schüttelfrost; Bilirubin Anstieg; Hypernatriämie; Hypermagnesiämie; Troponin Anstieg; Anstieg der Gamma Glutamyltransferase; Anstieg der Laktatdehydrogenase im Blut; Lipase Anstieg; Amylase Anstieg; Reaktionen im Zusammenhang mit einer Infusion. **Gelegentlich:** Follikulitis; Hämolytische Anämie; Hypophyseninsuffizienz; Hypogonadismus; Enzephalitis; Guillain Barré Syndrom; Optikusneuritis; Myasthenia gravis; Vogt Koyanagi Harada Syndrom; okuläre Hyperämie; Perikarderguss; Asthma; Pleuraerguss; Ösophagitis; Cholangitis; Pemphigoid; Psoriasis; Urtikaria; Myositis; Sjögren Syndrom; Polymyalgia rheumatica; rheumatoide Arthritis; systemischer Lupus erythematoses; Nephritis; Azoospermie; Anstieg des C reaktiven Proteins; Anstieg der Blutkörperchensenkungsgeschwindigkeit. **Selten:** Exokrine Pankreasinsuffizienz; Serositis. **Nicht bekannt:** Zöliakie.

Weitere Hinweise siehe Fachinformation. Verschreibungspflichtig. Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung über das nationale Meldesystem anzuzeigen. Pharmazeutischer Unternehmer: Bristol Myers Squibb Pharma EEIG; Plaza 254; Blanchardstown Corporate Park 2; Dublin 15; D15 T867; Irland. Stand: v01.

*Every time we care for a single person, we make the whole world better.*



# New ways to care.

At Pierre Fabre Laboratories, we have a passion for addressing clinical challenges through innovative solutions, keeping patients at the core of our efforts.

The fight against cancer is our main priority in medical care.

We take a holistic approach to cancer care focusing not only on treatment, but also prevention and support.

# Delcath®

Concentrate on what matters.



## Clinical & Scientific Publications

Scan for full access to the evidence library.

Scan below



Mit Unterstützung der ADO



Arbeitsgemeinschaft  
Dermatologische Onkologie  
**ADO**

## Dermato-Onkologie UPDATE 2027

**26.–27.02.2027**  
**2-TÄGIGER HYBRIDKURS**  
Meliá Hotel Berlin

**SAVE  
THE  
DATE**



**EADO**

European Association of  
Dermato Oncology

**23<sup>RD</sup>**

**EADO  
CONGRESS**

**April 15<sup>th</sup>–17<sup>th</sup>, 2027**

**HOFBURG, VIENNA**

**SAVE THE DATE**


ON-SITE CONGRESS

# Together into the future


Plan with us your next  
scientific event



istockphoto/piranka



(M) Freepik/Updyak



MedConcept Gesellschaft  
für medizinische Projekte mbH  
Friedenstraße 58, 15366 Neuenhagen



+49 3342 42689-30



info@medconcept.org



www.medconcept.org

**MEDCONCEPT** 

Experience since 1997

# IMPORTANT INFORMATION

## Internet Connection

Free Wi-Fi service will be available to all delegates within the Radisson Blu Hotel.

## Certificate of Attendance:

All registered attendees will receive a certificate of attendance within 10 days after the meeting via e-mail and after completing an evaluation survey. **Please note!** If you need to change your contact e-mail address, please come to the registration desk.

## Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area. **Should a name badge be lost, a replacement can be provided for a fee of € 25,00.**

## Daily Scan

To receive your daily CME credits please remember to scan yourself once a day at the registration desk. German participants must also register in the barcode list of the Hamburg Medical Association.

---